AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-7. (cancelled).

8. (currently amended) A compound of the formula:



Compound 2(a)

or a pharmaceutically acceptable salt thereof.

9. (currently amended) A compound of the formula II:



~~Formula II~~



Formula II

wherein A^1 is $-NH_2$, $-N=CH-R^{13}$, an amino acid or $-NH-R^{14}$, wherein R^{13} is hydrogen or phenyl, wherein the amino acid is attached via its nitrogen atom, and wherein R^{14} is selected from the group consisting of isopropyl, 1-(4-nitrophenyl)methyl, cyclohexyl, ~~and wherein said amino acid is attached via its nitrogen atom;~~



and



wherein R^{15} is selected from the group consisting of methyl, isopropyl, phenyl, 4-nitrophenyl, 1-aminoethyl, 1-amino-1-(4-hydroxyphenyl)methyl, 1-amino-2-(4-hydroxyphenyl)ethyl, 1-amino-2-methylpropyl, 2-pyrrolidinyl and 1-amino-2-hydroxyethyl;

~~Y^{20} is selected from the group consisting of ethene-1,2-diyl and~~



Z[1] is selected from the group consisting of:





R^{20} is selected from the group consisting of hydrogen and



~~Y^{30} is ethene-1,2-diyl or ethane-1,2-diyl~~; and

D^1 is hydroxy, methoxy or



and pharmaceutically acceptable salts thereof.

10. (currently amended) A compound selected from the group consisting of:



~~Compound 2(b)~~



Compound 2(c)



Compound 2(d)



Compound 2(e)



~~Compound 2(f)~~



Compound 2(g)



Compound 2(h)



Compound 2(i)



Compound 2(j)



~~Compound 2(k)~~



~~Compound 2(l)~~



~~Compound 2(m)~~



Compound 2(n)



Compound 2(o)



Compound 2(p)



Compound 2(q)



Compound 2(r)



Compound 2(s)



Compound 2(t)



Compound 2(u)



Compound 2(v)



Compound 2(w)



Compound 2(x)



Compound 2(y)



Compound 2(z)



Compound 2(aa)



Compound 2(ab)

11. (currently amended) A method for obtaining ~~producing~~ the compound of claim 8, comprising: ~~the steps of~~

(a) culturing ~~cultivating~~ cells derived from a *Streptomyces aizunensis* strain~~,~~ ~~incubating said cultured cells~~ aerobically and in a growth medium, whereby the compound of claim 8 is produced ~~for such time as is required for production of said compound of claim 8~~,

(b) extracting said medium of (a) with a solvent, and

(c) purifying the compound of claim 8 from the ~~crude~~ extract of (b), thereby obtaining the compound of claim 8.

12. (original) The method of claim 11 wherein said *Streptomyces aizunensis* strain is NRRL B-11277 or a mutant thereof.

13. (original) The method of claim 12 wherein said mutant is strain [C03]023 (deposit accession number IDAC 070803-1) or [C03U03]023 (deposit accession number IDAC 231203-02).

14.-15. (canceled).

16. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10~~1~~, and a pharmaceutically acceptable carrier.

17. (original) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 8, and a pharmaceutically acceptable carrier.

18. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9, and a pharmaceutically acceptable carrier.

19. (currently amended) A method of treating a fungal infection in a mammal, comprising administering to a mammal having a fungal infection ~~said mammal suffering from said infection,~~ a therapeutically effective amount of a compound of claim 8~~1~~.

20. (original) The method of claim 19 wherein said fungal infection is caused by *Candida albicans*.

21. (original) The method of claim 19 wherein said fungal infection is caused by a Candida sp., wherein said *Candida sp.* is selected from the group consisting of *C. glabrata*, *C. lusitaniae C. parapsilosis*, *C. krusei* and *C. tropicalis*.

22. (original) The method of claim 19 wherein said fungal infection is caused by an *Aspergillus sp.*, wherein said *Aspergillus sp.* is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

23. (currently amended) The method of claim 19 wherein said fungal infection is caused by a fungus selected from the group consisting of *Fusarium spp.*; *Scedosporium spp.*; *Cryptococcus spp.*; *Mucor ssp.~~ssp.~~*; *Histoplasma spp.*; *Trichosporon spp.*; *Blaspomyces spp.*; and ~~or~~ *S. cerevisiae*.

24. (currently amended) A method of treating a fungal infection in a mammal~~subject~~, comprising administering to a mammal having a fungal infection~~said subject suffering from said infection,~~ a therapeutically effective amount of a compound of claim 9~~1~~.

25. (currently amended) The method of claim 24 wherein said fungal infection is caused by ~~a fungus selected from the group consisiting of~~ *Candida albicans*~~, Candida sp., Aspergillus sp., Fusarium spp.; Scedosporium spp.; Cryptococcus spp.; Mucor ssp.; Histoplasma spp.; Trichosporon spp.; Blaspomyces spp.;~~ and *S. cerevisiae*.

26. (currently amended) The method of claim 24 wherein said fungal infection is caused by a *Candida sp.*, wherein said *Candida sp.* is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.

27. (currently amended) The method of claim 24 wherein said fungal infection is caused by an *Aspergillus sp.*, wherein said *Aspergillus sp.* is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

28. (new) The method of claim 24 wherein said fungal infection is caused by a fungus selected from the group consisting of *Fusarium spp.*; *Scedosporium spp.*; *Cryptococcus spp.*; *Mucor ssp.*; *Histoplasma spp.*; *Trichosporon spp.*; *Blaspomyces spp.*; and *S. cerevisiae*.

29. (new) A method of treating a fungal infection in a mammal, comprising administering to a mammal having a fungal infection a therapeutically effective amount of a compound of claim 10.

30. (new) The method of claim 29 wherein said fungal infection is caused by *Candida albicans*.

31. (new) The method of claim 29 wherein said fungal infection is caused by a Candida sp., wherein said *Candida sp.* is selected from the group consisting of *C. glabrata*, *C. lusitaniae C. parapsilosis*, *C. krusei* and *C. tropicalis*.

32. (new) The method of claim 29 wherein said fungal infection is caused by an *Aspergillus sp.*, wherein said *Aspergillus sp.* is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

33. (new) The method of claim 29 wherein said fungal infection is caused by a fungus selected from the group consisting of *Fusarium spp.*; *Scedosporium spp.*; *Cryptococcus spp.*; *Mucor ssp.*; *Histoplasma spp.*; *Trichosporon spp.*; *Blaspomyces spp.*; and *S. cerevisiae*.